Case Studies
 NitroMed
- Sold non-relevant patent right Ohmeda for $1 million within 90 days of getting assignment
- Internal investors heartened to bridge additional funds
- Completed two licensing transactions with J&J companies (>$30 mil. milestones)
- NO molecules for stent coating (Cordis)
- NO molecules for gastro protective effect with NSAID’s (Ortho-MCNeil)
- Subsequent private investment achieved which lasted until IPO
- Stock rose to market cap of >$25/share from $1.00 when Sage became involved
|
 Return to all case studies
|